DOCSLIB.ORG

Increased A2,6 Sialylation of N-Glycans in a Transgenic Mouse Model of Hepatocellular Carcinoma'

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Increased A2,6 Sialylation of N-Glycans in a Transgenic Mouse Model of Hepatocellular Carcinoma' (CANCER RESEARCH 57. 4249-4256. October I, 19971 Increased a2,6 Sialylation of N-Glycans in a Transgenic Mouse Model of Hepatocellular Carcinoma' Dominique Pousset, VéroniquePiller,Nicole Bureaud, Michel Monsigny, and Friedrich Nller@ Glycobiologie, Centre de Biophysique Moléculaire,F45071 OrlEans Cedex 02, France ABSTRACT AFP3 levels and in alkaline phosphatase or a rapid deterioration of liver function may be a clue to the presence of the neoplasm (2, 3). Liver cancer is one of the most frequent and lethal malignancies Therefore, the identification of reliable markers for the early diagnosis worldwide. Early detection is hampered by the absence of reliable mark of hepatocellular carcinoma may increase the success rates of surgical era. Mice transgenic for the SV4Olarge T antigen under the control of a liver-specific promoter spontaneously develop well-differentiated hepato resection and other therapies. The search for carbohydrate changes in cellular carcinomas between 8 to 10 weeks of age. They are excellent hepatocellular carcinomas has focused primarily on AFP to distin models to investigate the alterations of protein expression in the early guish the liver-specific glycoprotein from glycoforms that are secreted stages of tumor development and to follow these changes during tumor in other malignancies. It was found that fucosylation of the aspar progressionS In the present study, we analyzed the glycosylation changes agine-linked glucosamine residue of N-glycans was significantly in occurring during tumor development in transgenic mice expressing the creased on AlP from human hepatocellular carcinomas (4, 5). An 5V40 T antigen under the control of the antithrombin ifi promoter. The other fucose-related glycan marker, the Le@epitope, has been reported analysis of serum and liver glycoproteins by an ELISA type assay, using on the cell membranes of poorly differentiated hepatocellular carci the lectin from Sambucusnigra (SNA) as a probe, revealed the presence of nomas in patients expressing high levels of AlP (6, 7). No glycosy increased levels of Neu5Aca2,6Gal@31,4GlcNAc on N-glycans in the hi mor-bearing transgenic mice as compared to controls. On serum glyco lation-related markers have been found for well-differentiated hepa proteins the increase In a2,6 sialylation followed tumor progression, tocellular carcinomas, which generally do not express AFP. reaching up to 10 tImes control levels. However, significantly higher SNA The absence of specific markers makes it almost impossible to binding (2-fold) could already be observed on serum glycoproteins from study the early stages of tumor development in human patients at risk mice exhibiting only microscopically small neoplastic foci. On liver mem for hepatocellular carcinoma. Therefore, the development of animal brane glycoproteins, the increase in a2,6 sialylation was less pronounced, models for the study of tumorigenesis is crucial for our understanding reaching two to three times control values in 6-month-old mice. Western of early events occurring during this process. The first animal models blottingofsenun and liverproteins withradiolabeledSNAshowedthat all were liver cancers induced by chemical carcinogens in the rat (8). glycoproteins that bind the lectin In controls exhibit larger amounts of Since the advent of transgenic techniques, the model of choice has Neu5Aca2,6Gal@31,4GlcNAcon N-glycans in the tumor-bearing mice. This general increase in a2,6 sialylation on all glycoproteins is due to become the mouse expressing a viral or mutated cellular oncogene in the increased activity of the galactosideux2,6 slalyltransferase (ST6GaI I), a strictly tissue-specific manner (9, 10). which specifically transfers Neu5Ac residues in a2,6 linkage to For the study of hepatocellular carcinoma, mice expressing the Galfil,4GIcNAc units on N-glycans. As for the structures synthesized by early region (T/t antigen or Tag) of the SV4O genome under the the enzyme, the increase of ST6GaI I activity in the serum as well as in control of the promoter regions of the albumin, cs-antitrypsin, and liver microsomes of the transgenic mice followed tumor progression. AT!!! genes have been created. All of these mice develop well Interestingly, the activity ofthe galactoslde:a2,3 sialyltransferase (ST3Ga1 differentiated hepatocellular carcinomas (reviewed in Refs. 11 and ifi), whichusesthesameacceptorsubstrate(Gal@1,4GlcNAc),wasun 12). The tumor develops first in microscopically small foci at multiple changed in the earlier stages of tumor development but decreased in the sites throughout the liver. It is characterized by the classical sequence serum and in liver microsomes from later stages. Using a rat ST6GaI I cDNA as a probe, Northern blots of total RNA extracted from the livers ofevents: hyperplasia, dysplasia, adenoma, and carcinoma. In contrast ofcontrol and transgenic mice revealed an increased (4-fold) expression of to other transgenic models of hepatocellular carcinoma, the ATIII the ST6GaJI gene. The single transcripts detected In both normal and SV4O-Tag transgene-induced tumors occasionally develop lung me cancerous liver showed identical size. tastasis and thus show all of the characteristics of an advanced tumor. The proliferating foci develop into nodules that grow until the liver INTRODUCTION reaches about 10 times its normal size. The tumors are composed exclusively of hepatocytes without any elements of the biliary epithe Hepatocellular carcinoma is the most frequent cancer in many parts hum. The tumors are well differentiated, secrete normal amounts of of the world, whereas it is relatively uncommon in Europe or in the albumin, and do not express AFP (1 1). United States. It is rarely cured by surgical resection, and other Recently, a similar transgenic model of rat hepatocellular carci therapies are usually administered as part of clinical trials (1). Success noma has been reported, which shows also all of the characteristics of rate is low, however, due to the absence of other reliable early a well-differentiated tumor. In addition, the comparison of several diagnostics, and the most common primary diagnostic is the detection tumor markers from focal and neoplastic lesions of the livers of rats of an increase in hepatic mass. In about one-half of the patients at risk treated with chemical carcinogens and from transgenic rats revealed (cirrhosis or hepatitis B or C infection), a progressive increase in many similarities between the two experimental neoplasms ( 12). All of these reports clearly show that animals expressing the 5V40- Received 5/19/97; accepted 7/30/97. Tag in a strictly liver-specific manner are excellent models for hep Thecostsof publicationofthisarticleweredefrayedinpartby thepaymentofpage charges. This article must therefore be hereby marked advertisement in accordance with atocellular carcinoma and may, therefore, serve as experimental sys 18 U.S.C. Section 1734 solely to indicate this fact. tems to identify markers of tumorigenesis. Carbohydrate changes on I This work was supported by grants from the Association pour Ia Recherche sur Ic Cancer, Biotechnocentre, the Conseil Regional de la Region Centre, and the Ministèrede l'Enseignement SupéneurCtde Ia Recherche (to F. P.). D. P. is supported by a fellowship 3 The abbreviations used are: AFP, a-fetoprotein; SV4O-Tag, SV4O T antigen; ATIII, from the Association pour la Recherche sur le Cancer. antithrombin III; Neu5Ac. N-acetylneuraminic acid; Gal. galactose; GlcNAc, N-acetyl 2 To whom requests for reprints should be addressed, at Glycobiologie, Centre de glucosamine; ST6Ga1 I, CMP-Neu5Ac:Gal@3l,4GlcNAca2,6 sialyltransferase; ST3GaI Biophysique Moléculaire,rueCharles Sadron, F4507l Orleans Cedex 02, France. Phone: III, CMP-Neu5Ac:Gal@l,3(4)GlcNAca2,3 sialyltransferase: SNA, Sambucus nigra ag (33) 238 25 76 43; Fax: (33) 238 69 00 94; E-mail: [email protected]. glutinin; AGP, a1-acid glycoprotein; PMSF, phenylmethylsulfonyl fluoride. 4249 Downloaded from cancerres.aacrjournals.org on October 2, 2021. © 1997 American Association for Cancer Research. GLYCOSYLATIONINMURINEHEPATOCELLULARCARCINOMA glycoproteins and glycolipids are associated with tumor development The pellet was freeze-dried and extracted three times with methanol at 70°C (13, 14) and may be used as tumor markers (15, 16). However, very and dried in the vacuum at room temperature. The material was suspended in little is known about glycosylation changes in mouse hepatocellular 5 ml of Pronase buffer [150 mM Tris-HCI (pH 8.0), 75 mM NaCI, and 2 inst carcinoma. Therefore, we screened by lectin-ELISA serum and liver CaC12Iby vortexing and ultrasonication. A 50-pi aliquot of a solution of membrane glycoproteins from normal mice and from mice transgenic Pronase E (10 mg/mI in Pronase buffer) was added, and the mixture was kept at 37°Cfor20 h. After adjusting the pH to 8.0 with 2 si Tris-base, another for the T-antigen from SV4O under the dependence of the human aliquot of Pronase E was added, and the incubation continued for 24 h. The ATIII promoter and analyzed a variety of glycosyltransferases. The addition of Pronase and the incubation were repeated one more time. After specific activity of most glycosyltransferases tested was unchanged in centrifugation, the clear supernatant was heated in a boiling water bath for 5 the tumor-bearing mice, whereas the a2,6 sialyltransferase (ST6Gal I) mm and stored at 4°C.The Pronase digests were applied to a column of was dramatically increased. Because increased sialylation has been Sephadex
Load more

Recommended publications
  • Download (PDF)
    Tomono et al.: Glycan evolution based on phylogenetic profiling 1 Supplementary Table S1. List of 173 enzymes that are composed of glycosyltransferases and functionally-linked glycan synthetic enzymes UniProt ID Protein Name Categories of Glycan Localization CAZy Class 1 Q8N5D6 Globoside -1,3-N -acetylgalactosaminyltransferase 1 Glycosphingolipid Golgi apparatus GT6 P16442 Histo-blood group ABO system transferase Glycosphingolipid Golgi apparatus GT6 P19526 Galactoside 2--L-fucosyltransferase 1 Glycosphingolipid Golgi apparatus GT11 Q10981 Galactoside 2--L-fucosyltransferase 2 Glycosphingolipid Golgi apparatus GT11 Q00973 -1,4 N -acetylgalactosaminyltransferase 1 Glycosphingolipid Golgi apparatus GT12 Q8NHY0 -1,4 N -acetylgalactosaminyltransferase 2 O -Glycan, N -Glycan, Glycosphingolipid Golgi apparatus GT12 Q09327 -1,4-mannosyl-glycoprotein 4--N -acetylglucosaminyltransferase N -Glycan Golgi apparatus GT17 Q09328 -1,6-mannosylglycoprotein 6--N -acetylglucosaminyltransferase A N -Glycan Golgi apparatus GT18 Q3V5L5 -1,6-mannosylglycoprotein 6--N -acetylglucosaminyltransferase B O -Glycan, N -Glycan Golgi apparatus GT18 Q92186 -2,8-sialyltransferase 8B (SIAT8-B) (ST8SiaII) (STX) N -Glycan Golgi apparatus GT29 O15466 -2,8-sialyltransferase 8E (SIAT8-E) (ST8SiaV) Glycosphingolipid Golgi apparatus GT29 P61647 -2,8-sialyltransferase 8F (SIAT8-F) (ST8SiaVI) O -Glycan Golgi apparatus GT29 Q9NSC7 -N -acetylgalactosaminide -2,6-sialyltransferase 1 (ST6GalNAcI) (SIAT7-A) O -Glycan Golgi apparatus GT29 Q9UJ37 -N -acetylgalactosaminide -2,6-sialyltransferase
    [Show full text]
  • Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention?
    cancers Review Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention? Silvia Pietrobono * and Barbara Stecca * Tumor Cell Biology Unit, Core Research Laboratory, Institute for Cancer Research and Prevention (ISPRO), Viale Pieraccini 6, 50139 Florence, Italy * Correspondence: [email protected] (S.P.); [email protected] (B.S.); Tel.: +39-055-7944568 (S.P.); +39-055-7944567 (B.S.) Simple Summary: Sialylation is a post-translational modification that consists in the addition of sialic acid to growing glycan chains on glycoproteins and glycolipids. Aberrant sialylation is an established hallmark of several types of cancer, including breast, ovarian, pancreatic, prostate, colorectal and lung cancers, melanoma and hepatocellular carcinoma. Hypersialylation can be the effect of increased activity of sialyltransferases and results in an excess of negatively charged sialic acid on the surface of cancer cells. Sialic acid accumulation contributes to tumor progression by several paths, including stimulation of tumor invasion and migration, and enhancing immune evasion and tumor cell survival. In this review we explore the mechanisms by which sialyltransferases promote cancer progression. In addition, we provide insights into the possible use of sialyltransferases as biomarkers for cancer and summarize findings on the development of sialyltransferase inhibitors as potential anti-cancer treatments. Abstract: Sialylation is an integral part of cellular function, governing many biological processes Citation: Pietrobono, S.; Stecca, B. including cellular recognition, adhesion, molecular trafficking, signal transduction and endocytosis. Aberrant Sialylation in Cancer: Sialylation is controlled by the levels and the activities of sialyltransferases on glycoproteins and Biomarker and Potential Target for lipids. Altered gene expression of these enzymes in cancer yields to cancer-specific alterations of Therapeutic Intervention? Cancers glycoprotein sialylation.
    [Show full text]
  • Two Arabidopsis Proteins Synthesize Acetylated Xylan Invitro
    The Plant Journal (2014) 80, 197–206 doi: 10.1111/tpj.12643 FEATURED ARTICLE Two Arabidopsis proteins synthesize acetylated xylan in vitro Breeanna R. Urbanowicz, Maria J. Pena*,~ Heather A. Moniz, Kelley W. Moremen and William S. York* Complex Carbohydrate Research Center, University of Georgia, 315 Riverbend Road, Athens, GA 30602, USA Received 4 June 2014; revised 18 July 2014; accepted 1 August 2014; published online 21 August 2014. *For correspondence (e-mails [email protected]; [email protected]). SUMMARY Xylan is the third most abundant glycopolymer on earth after cellulose and chitin. As a major component of wood, grain and forage, this natural biopolymer has far-reaching impacts on human life. This highly acetylated cell wall polysaccharide is a vital component of the plant cell wall, which functions as a molecular scaffold, pro- viding plants with mechanical strength and flexibility. Mutations that impair synthesis of the xylan backbone give rise to plants that fail to grow normally because of collapsed xylem cells in the vascular system. Phenotypic analysis of these mutants has implicated many proteins in xylan biosynthesis; however, the enzymes directly responsible for elongation and acetylation of the xylan backbone have not been unambiguously identified. Here we provide direct biochemical evidence that two Arabidopsis thaliana proteins, IRREGULAR XYLEM 10–L (IRX10-L) and ESKIMO1/TRICOME BIREFRINGENCE 29 (ESK1/TBL29), catalyze these respective processes in vi- tro. By identifying the elusive xylan synthase and establishing ESK1/TBL29 as the archetypal plant polysaccha- ride O-acetyltransferase, we have resolved two long-standing questions in plant cell wall biochemistry.
    [Show full text]
  • Multiplexed Engineering Glycosyltransferase Genes in CHO Cells Via Targeted Integration for Producing Antibodies with Diverse Complex‑Type N‑Glycans Ngan T
    www.nature.com/scientificreports OPEN Multiplexed engineering glycosyltransferase genes in CHO cells via targeted integration for producing antibodies with diverse complex‑type N‑glycans Ngan T. B. Nguyen, Jianer Lin, Shi Jie Tay, Mariati, Jessna Yeo, Terry Nguyen‑Khuong & Yuansheng Yang* Therapeutic antibodies are decorated with complex‑type N‑glycans that signifcantly afect their biodistribution and bioactivity. The N‑glycan structures on antibodies are incompletely processed in wild‑type CHO cells due to their limited glycosylation capacity. To improve N‑glycan processing, glycosyltransferase genes have been traditionally overexpressed in CHO cells to engineer the cellular N‑glycosylation pathway by using random integration, which is often associated with large clonal variations in gene expression levels. In order to minimize the clonal variations, we used recombinase‑mediated‑cassette‑exchange (RMCE) technology to overexpress a panel of 42 human glycosyltransferase genes to screen their impact on antibody N‑linked glycosylation. The bottlenecks in the N‑glycosylation pathway were identifed and then released by overexpressing single or multiple critical genes. Overexpressing B4GalT1 gene alone in the CHO cells produced antibodies with more than 80% galactosylated bi‑antennary N‑glycans. Combinatorial overexpression of B4GalT1 and ST6Gal1 produced antibodies containing more than 70% sialylated bi‑antennary N‑glycans. In addition, antibodies with various tri‑antennary N‑glycans were obtained for the frst time by overexpressing MGAT5 alone or in combination with B4GalT1 and ST6Gal1. The various N‑glycan structures and the method for producing them in this work provide opportunities to study the glycan structure‑and‑function and develop novel recombinant antibodies for addressing diferent therapeutic applications.
    [Show full text]
  • Induced Structural Changes in a Multifunctional Sialyltransferase
    Biochemistry 2006, 45, 2139-2148 2139 Cytidine 5′-Monophosphate (CMP)-Induced Structural Changes in a Multifunctional Sialyltransferase from Pasteurella multocida†,‡ Lisheng Ni,§ Mingchi Sun,§ Hai Yu,§ Harshal Chokhawala,§ Xi Chen,*,§ and Andrew J. Fisher*,§,| Department of Chemistry and the Section of Molecular and Cellular Biology, UniVersity of California, One Shields AVenue, DaVis, California 95616 ReceiVed NoVember 23, 2005; ReVised Manuscript ReceiVed December 19, 2005 ABSTRACT: Sialyltransferases catalyze reactions that transfer a sialic acid from CMP-sialic acid to an acceptor (a structure terminated with galactose, N-acetylgalactosamine, or sialic acid). They are key enzymes that catalyze the synthesis of sialic acid-containing oligosaccharides, polysaccharides, and glycoconjugates that play pivotal roles in many critical physiological and pathological processes. The structures of a truncated multifunctional Pasteurella multocida sialyltransferase (∆24PmST1), in the absence and presence of CMP, have been determined by X-ray crystallography at 1.65 and 2.0 Å resolutions, respectively. The ∆24PmST1 exists as a monomer in solution and in crystals. Different from the reported crystal structure of a bifunctional sialyltransferase CstII that has only one Rossmann domain, the overall structure of the ∆24PmST1 consists of two separate Rossmann nucleotide-binding domains. The ∆24PmST1 structure, thus, represents the first sialyltransferase structure that belongs to the glycosyltransferase-B (GT-B) structural group. Unlike all other known GT-B structures, however, there is no C-terminal extension that interacts with the N-terminal domain in the ∆24PmST1 structure. The CMP binding site is located in the deep cleft between the two Rossmann domains. Nevertheless, the CMP only forms interactions with residues in the C-terminal domain.
    [Show full text]
  • Sialyltransferase of the 13762 Rat Mammary Ascites Tumor Cells1
    [CANCER RESEARCH 44, 1148-1152, March 1984] Sialyltransferase of the 13762 Rat Mammary Ascites Tumor Cells1 ThérèsePrattand Anne P. Sherblom2 Department of Biochemistry, University of Maine, Orano, Maine 04469 ABSTRACT The MAT-B1 and MAT-C1 sublines of the 13762 rat mammary adenocarcinoma are a suitable system for studying sialic acid The MAT-B1 and MAT-C1 ascites sublines of the 13762 rat metabolism. The 2 cell lines, originally derived from the same mammary adenocarcinoma differ in morphology, agglutinability solid tumor, show marked differences in ability to be transplanted with concanavalin A, and xenotransplantability. Both cell lines into mice, agglutinability with concanavalin A, and total sialic acid contain a major mucin-type glycoprotein, but the MAT-C1 (xen- content (19). Greater than 70% of the protein-bound sialic acid otransplantable) subline contains a 3-fold-greater content of sialic in both cell lines is due to a high-molecular-weight mucin-type acid on the glycoprotein than does the MAT-B1 (nonxeno- glycoprotein, ASGP-1 (16). The 0-linked chains have a core transplantable) subline. structure Gal(01-»4)GlcNAc(01-»6)[Gal(|31-»3)]GalNAc3 where The present work indicates that whole cells of both lines both galactose residues may be substituted with sialic acids incorporate radioactivity from labeled CMP-sialic acid into a linked («2—>3).4TheMAT-C1 subline contains much more of component which comigrates with the major glycoprotein by disialylated hexasaccharide than does the MAT-B1 subline,4 sodium dodecyl sulfate polyacrylamide gel electrophoresis, and whereas the MAT-B1 oligosaccharides are predominantly neutral that label incorporated by MAT-B1 cells is released by alkaline- but may contain sulfate as well as sialic acid (17).
    [Show full text]
  • LN-EPC Vs CEPC List
    Supplementary Information Table 5. List of genes upregulated on LN-EPC (LCB represents the variation of gene expression comparing LN-EPC with CEPC) Gene dystrophin (muscular dystrophy, Duchenne and Becker types) regulator of G-protein signalling 13 chemokine (C-C motif) ligand 8 vascular cell adhesion molecule 1 matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) chemokine (C-C motif) ligand 2 solute carrier family 2 (facilitated glucose/fructose transporter), member 5 eukaryotic translation initiation factor 1A, Y-linked regulator of G-protein signalling 1 ubiquitin D chemokine (C-X-C motif) ligand 3 transcription factor 4 chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant) solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 transcription factor 4 apolipoprotein D RAS guanyl releasing protein 3 (calcium and DAG-regulated) matrix metalloproteinase 1 (interstitial collagenase) DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked /// DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked transcription factor 4 regulator of G-protein signalling 1 B-cell linker interleukin 8 POU domain, class 2, associating factor 1 CD24 antigen (small cell lung carcinoma cluster 4 antigen) Consensus includes gb:AK000168.1 /DEF=Homo sapiens cDNA FLJ20161 fis, clone COL09252, highly similar to L33930 Homo sapiens CD24 signal transducer mRNA. /FEA=mRNA /DB_XREF=gi:7020079 /UG=Hs.332045 Homo sapiens cDNA FLJ20161 fis, clone COL09252, highly similar to L33930 Homo sapiens CD24 signal transducer mRNA
    [Show full text]
  • Protein & Peptide Letters
    696 Send Orders for Reprints to [email protected] Protein & Peptide Letters, 2017, 24, 696-709 REVIEW ARTICLE ISSN: 0929-8665 eISSN: 1875-5305 Impact Factor: 1.068 Glycan Phosphorylases in Multi-Enzyme Synthetic Processes BENTHAM Editor-in-Chief: SCIENCE Ben M. Dunn Giulia Pergolizzia, Sakonwan Kuhaudomlarpa, Eeshan Kalitaa,b and Robert A. Fielda,* aDepartment of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich NR4 7UH, UK; bDepartment of Molecular Biology and Biotechnology, Tezpur University, Napaam, Tezpur, Assam -784028, India Abstract: Glycoside phosphorylases catalyse the reversible synthesis of glycosidic bonds by glyco- A R T I C L E H I S T O R Y sylation with concomitant release of inorganic phosphate. The equilibrium position of such reac- tions can render them of limited synthetic utility, unless coupled with a secondary enzymatic step Received: January 17, 2017 Revised: May 24, 2017 where the reaction lies heavily in favour of product. This article surveys recent works on the com- Accepted: June 20, 2017 bined use of glycan phosphorylases with other enzymes to achieve synthetically useful processes. DOI: 10.2174/0929866524666170811125109 Keywords: Phosphorylase, disaccharide, α-glucan, cellodextrin, high-value products, biofuel. O O 1. INTRODUCTION + HO OH Glycoside phosphorylases (GPs) are carbohydrate-active GH enzymes (CAZymes) (URL: http://www.cazy.org/) [1] in- H2O O GP volved in the formation/cleavage of glycosidic bond together O O GT O O + HO O + HO with glycosyltransferase (GT) and glycoside hydrolase (GH) O -- NDP OPO3 NDP -- families (Figure 1) [2-6]. GT reactions favour the thermody- HPO4 namically more stable glycoside product [7]; however, these GS R enzymes can be challenging to work with because of their O O + HO current limited availability and relative instability, along R with the expense of sugar nucleotide substrates [7].
    [Show full text]
  • 1471-2164-8-41.Pdf
    BMC Genomics BioMed Central Research article Open Access Loss of Parp-1 affects gene expression profile in a genome-wide manner in ES cells and liver cells Hideki Ogino1,2, Tadashige Nozaki2, Akemi Gunji2, Miho Maeda3, Hiroshi Suzuki4, Tsutomu Ohta5, Yasufumi Murakami3, Hitoshi Nakagama2, Takashi Sugimura2 and Mitsuko Masutani*1,2 Address: 1ADP-ribosylation in Oncology Project, National Cancer Center Research Institute, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan, 2Biochemistry Division, National Cancer Center Research Institute, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan, 3Department of Biological Science & Technology, Faculty of Industrial Science & Technology, Tokyo University of Science, 2641, Yamazaki, Noda, Chiba 278- 8510, Japan, 4Chugai Pharmaceutical Co Ltd., 1-135, Komakado, Gotemba, Shizuoka, 412-0038, Japan and 5Center for Medical Genomics, National Cancer Center Research Institute, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan Email: Hideki Ogino - [email protected]; Tadashige Nozaki - [email protected]; Akemi Gunji - [email protected]; Miho Maeda - [email protected]; Hiroshi Suzuki - [email protected]; Tsutomu Ohta - [email protected]; Yasufumi Murakami - [email protected]; Hitoshi Nakagama - [email protected]; Takashi Sugimura - [email protected]; Mitsuko Masutani* - [email protected] * Corresponding author Published: 7 February 2007 Received: 5 August 2006 Accepted: 7 February 2007 BMC Genomics 2007, 8:41 doi:10.1186/1471-2164-8-41 This article is available from: http://www.biomedcentral.com/1471-2164/8/41 © 2007 Ogino et al; licensee BioMed Central Ltd.
    [Show full text]
  • Release of Glycosyltransferase and Glycosidase Activities from Normal and Transformed Cell Lines1
    [CANCER RESEARCH 41, 2611-2615, July 1981J 0008-5472/81 /0041-OOOOS02.00 Release of Glycosyltransferase and Glycosidase Activities from Normal and Transformed Cell Lines1 Wayne D. Klohs,2 Ralph Mastrangelo, and Milton M. Weiser Division of Gastroenterology and Nutrition, Department of Medicine, State University of New York at Buffalo, Buffalo, New York 14215 ABSTRACT Indeed, a cancer-associated isoenzyme of serum galactosyl transferase has been reported in humans and animals with The release of galactosyltransferase, sialyltransferase, and certain malignant cancers (24, 26). Bernacki and Kim (2) and several glycosidase activities into the growth media from sev Weiser and Podolsky (34) have suggested that such increases eral normal and transformed cell lines was examined. Six of in serum glycosyltransferase levels may be the consequence the seven cell lines released galactosyltransferase into their of both an increased production and release from the tumor culture media. Only the human leukemia CCRF-CEM cells cells, perhaps through cell surface shedding of the enzymes, failed to release demonstrable galactosyltransferase activity. but the validity of this supposition has yet to be demonstrated. Release of galactosyltransferase activity into the media closely It is also not clear whether the elevated levels of circulating paralleled the growth curves for all but the BHKpy cells. These glycosyltransferases perform any molecular or physiological cells continued to release peak levels of galactosyltransferase function relative to the malignant
    [Show full text]
  • Advances in Understanding Glycosyltransferases from A
    Available online at www.sciencedirect.com ScienceDirect Advances in understanding glycosyltransferases from a structural perspective Tracey M Gloster Glycosyltransferases (GTs), the enzymes that catalyse commonly activated nucleotide sugars, but can also be glycosidic bond formation, create a diverse range of lipid phosphates and unsubstituted phosphate. saccharides and glycoconjugates in nature. Understanding GTs at the molecular level, through structural and kinetic GTs have been classified by sequence homology into studies, is important for gaining insights into their function. In 96 families in the Carbohydrate Active enZyme data- addition, this understanding can help identify those enzymes base (CAZy) [1 ]. The CAZy database provides a highly which are involved in diseases, or that could be engineered to powerful predictive tool, as the structural fold and synthesize biologically or medically relevant molecules. This mechanism of action are invariant in most of the review describes how structural data, obtained in the last 3–4 families. Therefore, where the structure and mechanism years, have contributed to our understanding of the of a GT member for a given family has been reported, mechanisms of action and specificity of GTs. Particular some assumptions about other members of the family highlights include the structure of a bacterial can be made. Substrate specificity, however, is more oligosaccharyltransferase, which provides insights into difficult to predict, and requires experimental charac- N-linked glycosylation, the structure of the human O-GlcNAc terization of individual GTs. Determining both the transferase, and the structure of a bacterial integral membrane sugar donor and acceptor for a GT of unknown function protein complex that catalyses the synthesis of cellulose, the can be challenging, and is one of the reasons there are most abundant organic molecule in the biosphere.
    [Show full text]
  • Supplemental Table 1
    Supplemental Data Supplemental Table 1. Genes differentially regulated by Ad-KLF2 vs. Ad-GFP infected EC. Three independent genome-wide transcriptional profiling experiments were performed, and significantly regulated genes were identified. Color-coding scheme: Up, p < 1e-15 Up, 1e-15 < p < 5e-10 Up, 5e-10 < p < 5e-5 Up, 5e-5 < p <.05 Down, p < 1e-15 As determined by Zpool Down, 1e-15 < p < 5e-10 Down, 5e-10 < p < 5e-5 Down, 5e-5 < p <.05 p<.05 as determined by Iterative Standard Deviation Algorithm as described in Supplemental Methods Ratio RefSeq Number Gene Name 1,058.52 KRT13 - keratin 13 565.72 NM_007117.1 TRH - thyrotropin-releasing hormone 244.04 NM_001878.2 CRABP2 - cellular retinoic acid binding protein 2 118.90 NM_013279.1 C11orf9 - chromosome 11 open reading frame 9 109.68 NM_000517.3 HBA2;HBA1 - hemoglobin, alpha 2;hemoglobin, alpha 1 102.04 NM_001823.3 CKB - creatine kinase, brain 96.23 LYNX1 95.53 NM_002514.2 NOV - nephroblastoma overexpressed gene 75.82 CeleraFN113625 FLJ45224;PTGDS - FLJ45224 protein;prostaglandin D2 synthase 21kDa 74.73 NM_000954.5 (brain) 68.53 NM_205545.1 UNQ430 - RGTR430 66.89 NM_005980.2 S100P - S100 calcium binding protein P 64.39 NM_153370.1 PI16 - protease inhibitor 16 58.24 NM_031918.1 KLF16 - Kruppel-like factor 16 46.45 NM_024409.1 NPPC - natriuretic peptide precursor C 45.48 NM_032470.2 TNXB - tenascin XB 34.92 NM_001264.2 CDSN - corneodesmosin 33.86 NM_017671.3 C20orf42 - chromosome 20 open reading frame 42 33.76 NM_024829.3 FLJ22662 - hypothetical protein FLJ22662 32.10 NM_003283.3 TNNT1 - troponin T1, skeletal, slow LOC388888 (LOC388888), mRNA according to UniGene - potential 31.45 AK095686.1 CONFLICT - LOC388888 (na) according to LocusLink.
    [Show full text]